Dr. Black is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1515 Holcombe Blvd
Houston, TX 77030Phone+1 713-792-6161
Education & Training
University of Texas M D Anderson Cancer CenterFellowship, Urologic Surgical Oncology, 2005 - 2008
University of WashingtonResidency, Urology, 2001 - 2005- University of WashingtonResidency, Surgery, 1999 - 2001
Johannes Gutenberg University of Mainz Faculty of MedicineClass of 1997
Certifications & Licensure
American Board of Urology Urology
Royal College of Physicians and Surgeons, CanadaUrology
Clinical Trials
- Trial of Local Cystoscopic Injection of Tremelimumab Plus Systemic Durvalumab for High Risk Non-Muscle Invasive Bladder Cancer Start of enrollment: 2021 Sep 01
Roles: Contact, Principal Investigator
Publications & Presentations
PubMed
- Long-Term Recurrence Risk, Metastatic Potential, and Length of Cystoscopic Surveillance of Low-Grade Nonmuscle-Invasive Bladder Cancer.Eunice Villegas, Katherine Lajkosz, Shayan Din, Cynthia Kuk, Amy Chan
The Journal of Urology. 2025-03-01 - Impact of Tumor Stage on Oncologic Outcomes of High-grade Bacillus Calmette-Guérin Unresponsive Non-muscle-invasive Bladder Cancer Undergoing Bladder-sparing Therapies.Drupad Annapureddy, Jacob I Taylor, Ashish M Kamat, Michael A O'Donnell, Jeffrey Howard
European Urology Focus. 2025-02-07 - 2 citationsLong-term outcomes of bladder-sparing therapy vs radical cystectomy in BCG-unresponsive non-muscle-invasive bladder cancer.Jacob I Taylor, Ashish M Kamat, Michael A O'Donnell, Drupad Annapureddy, Jeffrey Howard
BJU International. 2025-02-01
Press Mentions
EAU 2018: Who Benefits from Neoadjuvant Chemotherapy and Who Needs Immediate Radical Treatment?March 20th, 2018
Expert Discusses Next Steps for Durvalumab in Bladder CancerAugust 23rd, 2017
Immune Cells the Missing Ingredient in New Bladder Cancer TreatmentJuly 24th, 2017- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
